Advanced Urothelial Carcinoma
Advertisement
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
KEYNOTE-361: Complete Response Outcomes With First-line Pembrolizumab or Platinum-Based Chemotherapy
A post-hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
Drs. Koshkin, Basu break down treatment considerations based on ctDNA status after radical cystectomy, among other factors.
Drs. Koshkin and Basu discuss how ctDNA are being evaluated for disease recurrence, response monitoring in advanced UC.
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.
Drs. Shoag and Zhu describe their recent analysis on the data supporting ICI use in patients with cisplatin-ineligible mUC.
After maintenance approval, an estimated 42.8% of patients received first-line ICI with either pembrolizumab or atezolizumab.
Dr. Rosenberg discusses EV plus pembrolizumab, how the combination is being investigated in clinical trials, and toxicity.
Clinical trials that evaluated pembrolizumab, avelumab, and nivolumab for urothelial carcinoma were analyzed.
IMvigor210 and IMvigor211 shed light on the association between irAEs and outcomes after receiving atezolizumab for aUC.
Long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the JAVELIN Bladder 100 trial.
Dr. Plimack discusses the results of her phase 2 study on hypomethylating agents, and gives a preview of research to come.
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC.
A study carried out whole-exome sequencing on tumor specimens taken from 88 patients with advanced UC treated with ICIs.
Dr Rana McKay shares how the approval of enfortumab vedotin plus pembrolizumab impacts patients with advanced UC.
Enfortumab vedotin-ejfv with pembrolizumab is now approved for patients with locally advanced or metastatic UC.
The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab as an immunotherapeutic boost.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726